Abbott: Prostatic Neoplasms trials

The registry lists 11 Prostatic Neoplasms studies with Abbott as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 2Phase 3 5No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate CancerCompletedNCT01081873Results posted
• Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)CompletedNCT01078545Results posted
• A Study of Leuprolide to Treat Prostate CancerCompletedNCT00626431Phase 3Results posted
• Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active SurveillanceCompletedNCT03502213
• Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate CancerTerminatedNCT03256630
• A Long Term Safety Study With AtrasentanCompletedNCT00127478Phase 2/3
• Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate CancerCompletedNCT00056654Not applicable
• Atrasentan in Treating Patients With Prostate CancerCompletedNCT00046943Phase 3
• Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical FailureCompletedNCT00038662Phase 2
• Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00036556Phase 3
• A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00036543Phase 3